Article
Tan and Buch have reviewed the approach to difficult to treat rheumatoid arthritis (D2T-RA), with a new EULAR definiation of D2T-RA to foster an approach rationale and concideration of treatment options.
All News
Article
NEJM has published study results showing that vitamin D3 supplementation does not significantly lower fracture risk (vs. placebo) when used in generally healthy adults.
Article
Krill oil supplements in knee osteoarthritis (OA) was shown to be superior to placebo in reducing knee pain, stiffness and function while increasing the omega-3 index.
Article
Litifilimab, a humanized monoclonal antibody against BDCA2, targets the BDCA2 receptor on plasmacytoid dendritic cells. When administered to patients with cutaneous lupus erythematosus (CLE) was shown reducing disease activity in CLE patients.
Article
The janus kinase inhibitor, upadacitinib, has been shown to significantly improve the signs and symptoms of non-radiographic axial spondyloarthritis (nr-AxSpA), extending the efficacy of UPA beyond classic ankylosing spondylitis.
Dr. John Cush
Tweet
102 #RA patients in low dz activity followed for a year - half usual care vs half using smartphone assisted Pt-initiated care. DAS28 slightly increased in both groups without signif difference; app group had less visits (1.7 v 2.8; p<0.001) https://t.co/txttFjjgla https://t.co/TideQ5tVjJ
Dr. John Cush
Tweet
Upadacitinib in non-radiographic Axial Spondyloarthritis
The janus kinase inhibitor, upadacitinib, has been shown to significantly improve the signs and symptoms of nr-AxSpA, extending the efficacy of UPA beyond classic ankylosing spondylitis.
https://t.co/BbvOSRxbXU https://t.co/z5QOaFKrxz
Dr. John Cush
Tweet
In the RECOVERY trial - 8156 hospitalized COVID-19 patients; those on baricitinib had significantly fewer deaths (12% vs 14% PBO) but the size of benefit was somewhat smaller than that suggested by previous trials. (adjusted rate ratio 0·87) https://t.co/EW7xLc9TLC https://t.co/Ahr7bwAQmJ
Dr. John Cush
Tweet
Risk of incident & recurrent H.Zoster higher after tofacitinib - Korean claims analysis of 11,720 seropos. RA pts Rx w/ bDMARD or tofacitinib (2011-19). 14% got HZ. Compared to other biologics (ABA), Tofa incr HZ (HR 2.5) & recurrence (HR 3.69) https://t.co/lDuqdtkIjR https://t.co/zJ3ArS3gGs
Dr. John Cush
Tweet
"He who has a strong enough why; can bear almost any how"
- Friedrich Nietzsche https://t.co/BOpO9MMijR
Dr. John Cush
Tweet
Upadacitinib (Rinvoq) Approved by European Commission for use in adults with active Non-Radiographic Axial Spondyloarthritis - 15 mg qd p.o. Approval based on Phase 3 SELECT-AXIS 2 nr-axSpA trial published in Lancet https://t.co/n3Pci5GyoA https://t.co/4aoSOc7xHd
Dr. John Cush
Tweet
QD Clinic- Still's (or Not): Fever, Joint pain & Itchy Eyes
30 yr. woman with high fevers, itchy eyes and Still's manifestations for 6 weeks.
Still's or Not?
https://t.co/kbzhCxYp7H https://t.co/FEUzdXxHoW
Dr. John Cush
Tweet
Not Still’s – Now What?
Your patient doesn't meet criteria for Still’s disease (AOSD or sJIA), now what should you do or consider?
https://t.co/xPXZVzTXJr https://t.co/7hmhXFh6O3
Dr. John Cush
Tweet
Approach to ILD in Myositis Syndromes
Mehta et al have published a full read review of managing ILD in patients with inflammatory myopathies, a heterogeneous group of syndromes connected by ILD and and increased morbidity and mortality risk.
https://t.co/MLBGL2ZqTk https://t.co/cdO2nHAK6h
Dr. John Cush
Tweet
Rheumatic Causes for Fever of Unknown Origin
Fever of unknown origin (FUO) represents a diagnostic challenge to many physicians and while cancer and infectious causes need to be excluded, rheumatic disorders are amongst the most common causes of FUO.
https://t.co/2tlibH3SHO https://t.co/QsmkfeGEvb
Dr. John Cush
Tweet
Physician Assistant Salaries -Amer Academy of Physician Assoc 2022 Report
Critical care $122,832
Emer Med $121,480
Surgery $121,400
Cardiology $118,000
Heme/Onc $117,297
Rheumatology $113,000
ID $113,000
GI $113,000
Pulm $112,900
PCP $112,000
https://t.co/14SafbtTGm https://t.co/1yuPI5pAYE
Dr. John Cush
Tweet
The FDA has extended its indications for ustekinumab (Stelara) for use in pediatric psoriatic arthritis aged 6 years and older. Pediatric PsA makes up 6% of all pediatric inflammatory arthritis pts. https://t.co/vTM4x53n7k https://t.co/aQcuMury2k
Dr. John Cush
Tweet
FDA has approved a topical PDE4 inhibitor Roflumilast (Zoryve) a 0.3% cream for use in Plaque Psoriasis (Age 12 and Older) https://t.co/qDuCgUwmZV https://t.co/c0a7723A1X https://t.co/v5T66iKnvc
Dr. John Cush
Tweet
THe microbiome differs between #AS (n 33) and AS-IBD(59) compared to IBD (105) patients. Study comparing feces & intesting Bx. Microbiome composition correlated with BASDAI and faecal calprotectin (FCP) levels. https://t.co/D4QCVVDK7G https://t.co/OJkeisycg0
Dr. John Cush
Tweet
Review of Clinical Trial measures in systemic sclerosis:
-RCTs focus on skin dz, ILD or Pulm HTN using mod. Rodnan skin (MRSS), 6-min walk
-FVC is surrogate measure for SSc-ILD
- Composites: CRISS, the EUSTAR-AI
-Future: Skin mRNA biomarkersTHBS1 and COMP https://t.co/KPLiNTSSZA https://t.co/YgvWuMiU4i
